KPIs & Operating Metrics(New)

Cash Flow Statement

Amortization Amortization Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Aurinia Pharmaceuticals (AUPH) Non-cash Items (2016 - 2020)

Aurinia Pharmaceuticals filings provide 3 years of Non-cash Items readings, the most recent being $79.9 million for Q3 2020.

On a quarterly basis, Non-cash Items rose 68.93% to $79.9 million in Q3 2020 year-over-year; TTM through Sep 2020 was $79.9 million, a 68.93% increase, with the full-year FY2019 number at -$65.5 million, down 43.58% from a year prior.
Non-cash Items hit $79.9 million in Q3 2020 for Aurinia Pharmaceuticals, up from $43.2 million in the prior quarter.
In the past five years, Non-cash Items ranged from a high of $79.9 million in Q3 2020 to a low of -$21.3 million in Q1 2020.
Median Non-cash Items over the past 3 years was $26.3 million (2019), compared with a mean of $28.1 million.
The widest YoY moves for Non-cash Items: up 68.93% in 2020, down 274.79% in 2020.
Aurinia Pharmaceuticals' Non-cash Items stood at $33.1 million in 2018, then soared by 42.76% to $47.3 million in 2019, then soared by 68.93% to $79.9 million in 2020.
The last three reported values for Non-cash Items were $79.9 million (Q3 2020), $43.2 million (Q2 2020), and -$21.3 million (Q1 2020) per Business Quant data.